MQS Management’s Regeneron Pharmaceuticals REGN Stock Holding History

MQS Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$257K	Buy	412 +121	+42%	+$82.4K	0.31%	168
2026 Q1	$225K	Buy	+291	New	+$223K	0.15%	309
2025 Q2	–	Sell	-710	Closed	-$450K	–	618
2025 Q1	$450K	Buy	+710	New	+$488K	0.26%	153
2024 Q4	–	Sell	-728	Closed	-$765K	–	325
2024 Q3	$765K	Buy	+728	New	+$810K	0.43%	42
2024 Q1	–	Sell	-436	Closed	-$383K	–	645
2023 Q4	$383K	Buy	+436	New	+$359K	0.21%	193
2023 Q3	–	Sell	-513	Closed	-$369K	–	587
2023 Q2	$369K	Buy	+513	New	+$396K	0.25%	154
2023 Q1	–	Sell	-631	Closed	-$455K	–	565
2022 Q4	$455K	Buy	+631	New	+$466K	0.31%	118
2022 Q3	–	Sell	-423	Closed	-$250K	–	554
2022 Q2	$250K	Buy	+423	New	+$275K	0.17%	264

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

MQS Management's REGN Position: Q2 2026 in Review

MQS Management increased its Regeneron Pharmaceuticals (REGN) stake by 42% in Q2 2026, buying an estimated $82.4K and bringing the position to 412 shares worth $257K. The position accounts for 0.31% of the portfolio, ranked #168.

MQS Management first reported a position in REGN in Q2 2022 and has held it in 8 quarters since. The position peaked at $765K in Q3 2024. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

MQS Management held 412 shares of Regeneron Pharmaceuticals worth $257K as of Q2 2026.
MQS Management bought 121 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $82.4K.
Regeneron Pharmaceuticals made up 0.31% of MQS Management's portfolio in Q2 2026, its #168 holding.
MQS Management first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 8 quarters since.
MQS Management's Regeneron Pharmaceuticals position peaked at $765K in Q3 2024.
1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on MQS Management's 13F filing for Q2 2026, filed 7 Aug 2026.